Ukusasaza i-large B-cell lymphoma (DLBCL), i-NOS, i-GCB subtype, inkqubo ye-nervous central central lymphoma-01

NgoDisemba ka-2019, uMnu. Wang, utitshala ovela eNortheast China, waqala ukuba neentloko ezibuhlungu. Ngomhla we-19 kweyoMnga, ngo-2019, iimvavanyo zokuxilonga zatyhila oku kulandelayo: I-PET-CT ibonise isithunzi soxinano kunye nokwanda okukhulu kwe-FDG metabolism kwindawo yasekhohlo ye-frontal lobe kunye ne-corpus callosum knee area (malunga ne-3.4 * 1.9 cm, i-SUVmax = 34.4). I-Biopsy kunye ne-immunohistochemistry ziqinisekisile i-diffuse large B-cell lymphoma (i-DLBCL, i-NOS, i-GCB subtype), kunye ne-immunophenotype ebonisa i-Ki67 (50% +), i-CD19 (+), i-CD20 (+), i-PAX5 (+), i-CD79 (+), i-MUM1 (+), i-BCL (+), i-CD10 (-/+), i-CD2 (minor +). Uhlalutyo lwe-cerebrospinal fluid lubonise iiseli ze-lymphoid ezingavuthwanga eziyi-6% ezinokuguquguquka kwesimo. Ukuxilongwa yayiyi-primary central nervous system lymphoma (i-DLBCL, i-GCB subtype).

Emva kokuphanda ngeendlela zonyango kwi-intanethi, uMnu. Wang wafunda ngezakhono ze-immunotherapy ze-BIOOCUS Medical Group waza wafuna ulwazi lwabo ngokukhawuleza. Emva kokuhlolwa ngokucokisekileyo komzimba kunye nohlalutyo olucokisekileyo lweqela leengcali zesibhedlele, kwagqitywa ekubeni uMnu. Wang uza kuthatha inxaxheba kuvavanyo lweklinikhi lonyango lwe-CART, ngakumbi kusetyenziswa iiseli ze-CD19 CART. Wafumana i-autologous CD19 CAR-T cell infusion nge-24 ka-Epreli 2023. Ngomhla wama-30 kuJulayi 2023, wavavanywa ukuba ufumene i-complete remission (CR) kwaye ukususela ngoko ubuyele kubomi obuqhelekileyo.